View Item 

Show simple item record

Tacrolimus Toxicity Associated with Concomitant Metoclopramide Therapy
dc.contributor.authorPrescott, William A.en_US
dc.contributor.authorCallahan, Brian L.en_US
dc.contributor.authorPark, Jeong M.en_US
dc.date.accessioned2012-03-16T16:02:03Z
dc.date.available2012-03-16T16:02:03Z
dc.date.issued2004-04en_US
dc.identifier.citationPrescott, William A.; Callahan, Brian L.; Park, Jeong M. (2004). "Tacrolimus Toxicity Associated with Concomitant Metoclopramide Therapy." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 24(4). <http://hdl.handle.net/2027.42/90417>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90417
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherDrug Interactionen_US
dc.subject.otherTacrolimusen_US
dc.subject.otherMetoclopramideen_US
dc.subject.otherGastric Motilityen_US
dc.titleTacrolimus Toxicity Associated with Concomitant Metoclopramide Therapyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy Services, College of Pharmacy, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.identifier.pmid15098810en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90417/1/phco.24.5.532.33357.pdf
dc.identifier.doi10.1592/phco.24.5.532.33357en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceUndre NA. Pharmacokinetics of tacrolimus‐based combination therapies. Nephrol Dial Transplant 2003; 18 ( suppl 1 ): i12 – 15.en_US
dc.identifier.citedreferenceVenkataramanan R., Swaminathan A., Prasad T., et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404 – 30.en_US
dc.identifier.citedreferenceKelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: A new immunosuppressive agent. Am J Health-Syst Pharm 1995; 52: 1521 – 35.en_US
dc.identifier.citedreferenceWinkler M., Ringe B., Baumann J., Loss M., Wonigeit K., Pichlmayr R. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994; 40: 2247 – 53.en_US
dc.identifier.citedreferenceBackman L., Nicar M., Levy M., et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994; 57: 519 – 25.en_US
dc.identifier.citedreferenceVenkataramanan R., Shaw LM, Sarkozi L., et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41: 542 – 51.en_US
dc.identifier.citedreferenceWinkler M., Jost U., Ringe B., Gubernatis G., Wonigeit K., Pichlmayr R. Association of elevated FK 506 plasma levels with nephrotoxicity in liver‐grafted patients. Transplant Proc 1991; 23: 3153 – 5.en_US
dc.identifier.citedreferenceChristians U., Jacobsen W., Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813 – 51.en_US
dc.identifier.citedreferencePrasad TN, Stiff DD, Subbotina N., et al. FK 506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 1994; 84: 35 – 46.en_US
dc.identifier.citedreferenceFloren LC, Bekersky I., Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41 – 9.en_US
dc.identifier.citedreferenceMoreno M., Latorre A., Manzanares C., et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant Proc 1999; 31: 2252 – 3.en_US
dc.identifier.citedreferenceKiuchi T., Tanaka K., Inomata Y., et al. Experience of tacrolimus‐based immunosuppression in living‐related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Transplant Proc 1996; 28: 3171 – 2.en_US
dc.identifier.citedreferenceChenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograft dysfunction associated with rifampin‐tacrolimus interaction. Ann Pharmacother 2000; 34: 27 – 31.en_US
dc.identifier.citedreferenceHebert MF, Fisher RM, Marsh CL, Dressler D., Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91 – 6.en_US
dc.identifier.citedreferenceFurlan V., Perello L., Jacquemin E., Debray D., Taburet AM. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995; 59: 1217 – 18.en_US
dc.identifier.citedreferenceHashimoto Y., Sasa H., Shimomura M., Inui K. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 1998; 15: 1609 – 13.en_US
dc.identifier.citedreferenceUndre NA, Stevenson P., Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999; 31 ( suppl 7A ): 21S – 4.en_US
dc.identifier.citedreferenceBekersky I., Dressler D., Mekki QA. Effect of low‐ and high‐fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41: 176 – 82.en_US
dc.identifier.citedreferenceBekersky I., Dressler D., Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41: 289 – 97.en_US
dc.identifier.citedreferenceMaes BD, Lemahieu W., Kuypers D., et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002; 2: 989 – 92.en_US
dc.identifier.citedreferenceBerengue Iglesias J., López‐Espinosa JA, Ortega‐López J., et al. Two‐ to three‐fold increase in blood tacrolimus (FK506) levels during diarrhea in liver‐transplanted children. Clin Transplant 2003; 17: 249 – 53.en_US
dc.identifier.citedreferenceFujisawa Healthcare Inc. Prograf (tacrolimus) prescribing information. Deerfield, IL; 2002.en_US
dc.identifier.citedreferenceWadhwa NK, Schroeder TJ, O'Flaherty E., Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation 1987; 43: 211 – 13.en_US
dc.identifier.citedreferenceA. H. Robins Co. Reglan (metoclopramide) prescribing information. Richmond, VA; 2001.en_US
dc.identifier.citedreferenceNaranjo CA, Busto U., Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239 – 45.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.24.5.532.33357.pdf
Size:
89.86KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.